The COVID-19 pandemic has disproportionately impacted immunocompromised patients.
This diverse group is at increased risk for impaired vaccine responses, progression to …

Immunocompromised patients, such as those with a haematological malignancy, are at
higher risk of SARS‐CoV‐2 infection, severe outcomes and mortality. Tixagevimab …

Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

Background: Tixagevimab/cilgavimab (TGM/CGM) are neutralizing monoclonal antibodies
(mAbs) directed against different epitopes of the receptor-binding domain of the SARS-CoV …

Background Immunocompromised individuals with hematological malignancy have
increased risk for poor outcomes and death from severe acute respiratory syndrome …

Abstract Coronavirus disease 2019 (COVID-19) was declared a global pandemic in March
2020, which precipitated urgent public health responses. The causative agent, SARS-CoV …

Introduction The effect of tixagevimab/cilgavimab (Evusheld™; AstraZeneca, UK) should be
evaluated in the context of concurrent outbreak situations. Methods For serologic …

Importance Pre-exposure prophylaxis with neutralizing SARS-CoV-2 monoclonal antibodies
(mAbs PrEP) prevents infection and reduces hospitalizations and the duration thereof for …

Patients affected by myelofibrosis (MF) or polycythemia vera (PV) and treated with ruxolitinib
are at high risk for severe coronavirus disease 2019. Now a vaccine against the virus SARS …

Abstract AZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal
antibodies for pre-exposure prophylaxis of severe acute respiratory syndrome coronavirus 2 …